INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essenlial thrombocythemia myelofibrosis (Post-PV/ET MF)

被引：13
|
作者：
Verstovsek, Srdan [1 ]
Kantarjian, Hagop [1 ]
Pardanani, Animesh
Thomas, Deborah [1 ]
Cortes, Jorge [1 ]
Mesa, Ruben [2 ]
Redman, John [3 ]
Staschen, Carl-Michael [3 ]
Fridman, Jordan [3 ]
Vaddi, Kris [3 ]
Tefferi, Ayalew [2 ]
机构：
[1] MD Anderson Canc Ctr, Leukemia Dept, Houston, TX USA
[2] Mayo Clin, Dept Hematol, Rochester, MN USA
[3] Incyte Corp, Wilmington, DE USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.558.558
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
558
引用
收藏
页码：171A / 171A
页数：1
相关论文
共 50 条
  • [21] PHASE II STUDY OF CEP-701, AN ORALLY AVAILABLE JAK2 INHIBITOR, IN PATIENTS WITH PRIMARY MYELOFIBROSIS AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
    Santos, F. P. S.
    Kantarjian, H.
    Jain, N.
    Thomas, D.
    Garcia-Manero, G.
    Cortes, J.
    Verstovsek, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 439 - 439
  • [22] Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis
    Verstovsek, Srdan
    Tefferi, Ayalew
    Korriblau, Steven
    Thomas, Deborah
    Cortes, Jorge
    Ravandi-Kashani, Farhad
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    BLOOD, 2007, 110 (11) : 1037A - 1037A
  • [23] Primary myelofibrosis (PMF), post polycythernia vera myelotibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
    Mesa, Ruben A.
    Verstovsek, Srdan
    Cervantes, Francisco
    Barosi, Giovanni
    Reilly, John T.
    Dupriez, Brigitte
    Levine, Ross
    Le Bousse-Kerdiles, Marie-Caroline
    Wadleigh, Martha
    Campbell, Peter J.
    Silver, Richard T.
    Vannucchi, Alessandro M.
    Deeg, H. Joachim
    Gisslinger, Heinz
    Thomas, Deborah
    Odenike, Olatoyosi
    Solberg, Lawrence A.
    Gotlib, Jason
    Hexner, Elizabeth
    Nimer, Stephen D.
    Kantarjian, Hagop
    Orazi, Attilio
    Vardiman, James W.
    Thiele, Juergen
    Tefferi, Ayalew
    LEUKEMIA RESEARCH, 2007, 31 (06) : 737 - 740
  • [24] EVIDENCE OF EFFICACY OF RAD001, AN INHIBITOR OF MTOR, IN A PHASE I/II STUDY IN PRIMARY MYELOFIBROSIS (PMF) AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PPV/PET MF)
    Vannucchi, M.
    Guglielmelli, P.
    Lupo, L.
    Finazzi, M. C.
    Tozzi, L.
    Biamonte, F.
    Antonioli, E.
    Bogani, C.
    Pieri, L.
    Gattoni, E.
    Masciulli, A.
    Paratore, S.
    Susini, M. C.
    Finazzi, G.
    Marchioli, R.
    Rambaldi, A.
    Barbui, T.
    Bosi, A.
    Barosi, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 472 - 472
  • [25] Durable Responses with the JAK1/JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU)
    Verstovsek, Srdan
    Passamonti, Francesco
    Rambaldi, Alessandro
    Barosi, Giovanni
    Rosen, Peter J.
    Levy, Richard
    Bradley, Edward
    Garrett, William
    Vaddi, Kris
    Contel, Nancy
    Sandor, Victor
    Huber, Reid Michael
    Schacter, Lee P.
    Rumi, Elisa
    Gattoni, Elisabetta
    Antonioli, Elisabetta
    Pieri, Lisa
    Cazzola, Mario
    Kantarjian, Hagop
    Barbui, Tiziano
    Vannucchi, Alessandro M.
    BLOOD, 2010, 116 (21) : 142 - 143
  • [26] Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia
    Gowin, Krisstina L.
    Dueck, Amylou C.
    Mascarenhas, John O.
    Hoffman, Ronald
    Reeder, Craig B.
    Camoriano, John
    Gano, Katherine
    Ghurye, Vineta
    Reddy, Sravan Nagi
    Koenig, Patricia
    Fauble, Veena
    Tibes, Raoul
    Mesa, Ruben
    BLOOD, 2014, 124 (21)
  • [27] Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)
    Verstovsek, Srdan
    Mesa, Ruben A.
    Rhoades, Susanne Kloeker
    Giles, Jennifer L. K.
    Pitou, Celine
    Jones, Emma
    Walgren, Richard A.
    Prchal, Josef T.
    BLOOD, 2011, 118 (21) : 1213 - 1214
  • [28] A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)
    Mascarenhas, John O.
    Borate, Uma
    Bose, Prithviraj
    Byrd, John C.
    Garcia, Jacqueline S.
    Grunwald, Michael R.
    Hobbs, Gabriela S.
    Hoffman, Ronald
    Kuykendall, Andrew T.
    Mesa, Ruben A.
    Oh, Stephen
    Rampal, Raajit
    Yacoub, Abdulraheem
    Steensma, David P.
    BLOOD, 2024, 144 : 31471 - 31473
  • [29] Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis
    Komrokji, Rami S.
    Wadleigh, Martha
    Seymour, John F.
    Roberts, Andrew W.
    To, Luen Bik
    Zhu, Huan J.
    Mesa, Ruben A.
    BLOOD, 2011, 118 (21) : 130 - 131
  • [30] Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Santos, Fabio P. S.
    Kantarjian, Hagop M.
    Jain, Nitin
    Manshouri, Taghi
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    Kennedy, Debra
    Estrov, Zeev
    Cortes, Jorge
    Verstovsek, Srdan
    BLOOD, 2010, 115 (06) : 1131 - 1136
12345